Return to search results.
Complete title: Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML
|Research Study Number||2449.00|
|Principal Investigator||Roland Walter, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- Diagnosis of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12), (promyelocytic leukemia [PML]/retinoic acid receptor [RAR]), or variants according to the 2008 World Health Organization (WHO) classification
- Currently undergoing AML-like intensive induction or re-induction chemotherapy, or is planned to start such therapy within 1 week
- Provide signed written informed consent
- Patients can be repeatedly enrolled in this protocol (e.g. for induction and 1st or subsequent salvage therapy)
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
Other exclusion criteria may apply.
Acute Lymphoid Leukemia (ALL); Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Leukemia; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.